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To the Editor: We read with great interest the article by
Mathieu [1], which discusses whether vitamin D is important
in diabetes. The author comes to several conclusions. The first
is that severe vitamin D deficiency should be avoided in
diabetes. We agree that the evidence is compelling. On the
role for vitamin D supplementation above the threshold of
vitamin D deficiency, it is concluded that high doses of
1,25-dihydroxyvitamin D reduce the incidence of diabetes in
primary prevention studies in animal models. From this the
author goes on to argue that carefully designed prospective
placebo-controlled and randomised trials are required to
provide definite answers as to the sense and non-sense of
vitamin D supplementation in individuals affected by or at risk
of type 1 and type 2 diabetes.
We completely agree: such trials are urgently needed, not
only because science has already posed the question, but
also because more and more people are actually supple-
menting themselves and their children on the basis of
currently unjustified messages in the lay press.
The author mentions hypercalcaemia, hypercalciuria and
kidney stones as potential adverse consequences of injudi-
cious vitamin D supplementation. At this point we would
like to add one other potentially even more important
concern regarding the injudicious use of vitamin D
supplementation. It is well known that even mild prolonged
increases in plasma calcium and plasma phosphate concen-
trations adversely affect the process of atherosclerotic
calcification to an appreciable extent [2, 3]. Such changes
could easily occur in response to vitamin D supplementa-
tion, increasing the already greater known risk of athero-
sclerotic vascular events in patients with diabetes and in
persons at increased risk of developing diabetes [4, 5]. It
would therefore be highly relevant if future clinical trials on
vitamin D supplementation were to include assessment of
surrogate markers of atherosclerosis, measures of arterial
calcification and assessment of cardiovascular events.
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